Stephen Lau

Stephen Lau is a seasoned biotech C-suite executive and entrepreneur with extensive experience in fundraising and deal-making. They founded BioClin Therapeutics, leading it to a successful acquisition by Fusion Pharmaceuticals and contributing to significant capital raises totaling $80 million. Previously, Lau held key roles at prominent companies such as Amgen and Anthera Pharmaceuticals, managing major licensing deals and overseeing growth through IPO. Currently, Lau serves as Chief Business Officer at Frontera Therapeutics and is a board member at Cognigenics, while pursuing a Master’s degree in Immunology at the University of California, Davis.